References
Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R (2012) Perioperative management of antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141:e326S–e350S
Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510
Schulman S, Crowther MA (2012) How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 119:3016–3023
Spyropoulos AC, Douketis JD (2012) How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 120:2954–2962
OpenEpi (2009) Open source epidemiologic statistics for public health [computer program], version 3. Rollins School of Public Health, Emory University, Atlanta, GA
Jaffer AK, Ahmed M, Brotman DJ, Bragg L, Seshadri N, Qadeer MA, Klein A (2005) Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis 20:11–16
Spyropoloulos AC (2012) Pro: “bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery”. J Thromb Haemost 108:213–216
Douketis JD (2012) Contra: “bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery”. J Thromb Haemost 108:213–216
Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC (2012) Periprocedural heparin bridging in patients receiving vitamin K antagonists systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126:1630–1639
Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AG, Bates SM, Desjardins L, Douketis J, Kahn SR, Solymoss S, Wells PS (2004) Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 110:1658–1663
Skeith L, Taylor J, Lazo-Langner A, Kovacs MJ (2012) Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study. J Thromb Haemost 10:2298–2304
Disclosures
A. Lazo-Langner has received honoraria from Pfizer Inc., Boehringer-Ingelheim and Leo Pharma. The other authors state they have no conflict of interest
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Skeith, L., Lazo-Langner, A. & Kovacs, M.J. The equipoise of perioperative anticoagulation management: a Canadian cross-sectional survey. J Thromb Thrombolysis 37, 411–413 (2014). https://doi.org/10.1007/s11239-013-0960-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-013-0960-6